$AEMD SAN DIEGO, Jan. 12, 2016 /PRNewswire/ -- Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc. (AEMD), announced today that it has agreed to participate in a clinical research study to establish methods for detecting and diagnosing chronic traumatic encephalopathy (CTE) during life as well as examining risk factors for CTE. CTE is a disease of the brain often found in athletes, military veterans, and others with a history of repetitive head impacts. At present, CTE can only be definitively diagnosed through post-mortem examination of brain tissue. #CTE #collaboration #Aethlon Medical

http://finance.yahoo.com/news/aethlon-medical...00370.html